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MHC class I molecules present cytosolic peptides to class I-restricted CTLs. Shortly after their generation in the cytosol, peptides are translocated to the lumen of the ER by the transporter of antigen presentation (TAP) peptide transporter and loaded onto peptide-receptive MHC class I complexes with the assistance of a variety of chaperones, including calreticulin, ERp57, and Tapasin (1) (2) (3) (4) . Stably conformed and peptide-fi lled class I complexes then egress from the ER to the cell surface for recognition by CD8 + T cells.
Most MHC class I allomorphs require peptides that are 8-10 amino acids in length for their stable assembly in the ER and transport to the cell surface (5) . Therefore, cells must be capable of degrading the vast majority of intracellular proteins into peptides that meet this strict length requirement. Proteasomes appear to be responsible for the initial proteolytic attack of most proteins and defective translation products that are degraded in the cytosol (6) (7) (8) (9) . Purifi ed proteasomes can generate peptides that are between 2 and 25 amino acids in length, but only ‫%51ف‬ of these peptides are of the correct size for optimal class I binding (10, 11) . Although it has been well established that proteasomes are responsible for generating the fi nal COOH terminus of peptide epitopes, they typically generate peptides with NH 2 -terminal extensions (12) . This tendency for generating precursors with NH 2 -terminal extensions may be enhanced for a version of the proteasome, termed the immunoproteasome, containing catalytic subunits that are induced by IFN-γ (11, 12) . These findings suggested that many peptides generated by the proteasome need to be trimmed, either before or after transport to the ER lumen, to the optimal length for binding with class I molecules. Recent studies have provided evidence for a role of both cytoplasmic and ER-resident proteases in trimming peptide precursors (9, 13, 14) . Emerging evidence indicates that relatively long proteasome products (>15 amino acids in length) are shortened in the cytosol by the NH 2 -terminal exopeptidase tripeptidyl peptidase II and that peptides with relatively short NH 2 -terminal extensions may be further trimmed by cytosolic aminopeptidases and endopeptidases (13, 14) . Although cytosolic peptidases trim a substantial proportion of precursor peptides to the correct size for binding with class I, many peptides enter the ER lumen with NH 2 -terminal extensions (15) . This may be caused, at least in part, by the preference of TAP to translocate peptides between 8 and 16 amino acids in length (16) . Although evidence for NH 2 -terminal peptidase activity in the ER has been available for more than a decade (17, 18) , the peptidases involved have eluded identifi cation until recently (19) (20) (21) (22) . ER-associated aminopeptidase (ERAP)1, also called ER aminopeptidase associated with antigen processing, is a ubiquitous, IFN-γ-inducible metallopeptidase that catalyzes the sequential removal of diverse NH 2 -terminal residues from peptide precursors (19) (20) (21) (22) . A second ER-resident, IFN-γ-regulated aminopeptidase, ERAP2, with more restricted tissue distribution, has been identifi ed in humans but appears to be absent in rodents (22) .
Apart from its inability to cleave the X-Pro (X denotes any amino acid) peptide bond, ERAP1 appears to have relatively little sequence selectivity (19, 22, 23) . However, one striking and unique feature of ERAP1 is that it effi ciently trims NH 2 terminally extended peptides but spares most peptides that are eight amino acid residues or shorter (20, 21, 24) , suggesting that ERAP1 favors the generation of peptides that are of the optimal size for binding with class I. Nevertheless, in some cases, recombinant ERAP1 destroyed cognate peptide epitopes (20, 21) . Consistent with these fi ndings, reduction of ERAP1 expression by RNA interference resulted in defective presentation of several peptide epitopes (19, 21, 22) but did not aff ect or even enhance presentation of some other epitopes (19) . Moreover, whether ERAP1 expression infl uences the levels of class I molecules displayed at the cell surface remains controversial. ERAP1 gene silencing in murine cells resulted in a reduction in the surface expression of H-2K k and H-2L d molecules (19) , whereas ERAP1 silencing in human HeLa cells or ERAP1 overexpression in monkey COS cells had no eff ect on H-2K b cell surface expression (21) . One group reported that ERAP1 silencing in HeLa cells resulted in an increase in HLA-A, HLA-B, and HLA-C surface expression (21) , whereas another group found a modest reduction in HLA class I surface expression (22) . The eff ects of ERAP1 silencing on the IFN-γ-induced expression of class I molecules are also controversial (21, 22) .
The cell lines that have been used to study ERAP1 function likely express nonphysiological levels of antigen-processing factors that may impact the interpretation of the results obtained. For example, diff erences in the expression levels of ERAP2 among distinct HeLa cell lines have been observed (9) . In addition, studies with RNA interference have intrinsic drawbacks that may complicate data interpretation (25) . Moreover, cell lines do not permit analysis of ERAP1 function by professional APCs or to determine its role in the generation of CTL responses in vivo. As an approach to clarify these issues, we generated a mouse strain with a targeted disruption in the ERAP1 gene. Analysis of these animals indicated defects in the surface expression of class Ia and class Ib molecules, class I-restricted antigen presentation, and the generation of CTL responses. These fi ndings reveal an important in vivo role of ERAP1 in optimizing peptides for surface display by MHC class I molecules.
RESULTS

Generation of ERAP1 mutant mice
ERAP1-defi cient mice were generated by replacing a 600-bp fragment of the ERAP1 gene, containing the sequence encoding the putative active site of ERAP1, with a neomycin resistance cassette (Fig. 1, A-C (Fig. 1 D) and immunoblotting ( Fig. 1 E) , respectively. Because ERAP1 has been suggested to participate in several functions unrelated to antigen processing (26-28), we evaluated mice for obvious abnormalities. However, mice appeared healthy, were fertile, and we were unable to detect any obvious anatomical or developmental defects.
Impact of ERAP1 defi ciency on class I cell surface expression
To evaluate the eff ects of ERAP1 defi ciency on steady-state levels of MHC class I cell surface expression, we stained cells from wild-type and mutant animals with class I-specifi c antibodies. We found a reproducible reduction in the surface expression of H-2K b and H-2D b molecules on total mononuclear cells in the spleen, lymph node, and blood; on splenic DCs, T cells, and B cells (Fig. 2 , A-C); and on fi broblast cell lines derived from these animals (Fig. 2 F) .[ I D ] F I G 2 [ / I D ] Levels of H-2K b and H-2D b were reduced ‫04ف‬ and 50%, respectively. We also found a signifi cant reduction in the extent of surface display of the nonclassical class I (class Ib) molecule Qa-2 ‫%53ف(‬ reduction as compared with wild-type cells; Fig. 2 , A-C), which is ubiquitously expressed and binds with a wide array of nonameric peptides (29, 30) .
IFN-γ induces the transcription of MHC class I genes and a variety of antigen processing-related genes, including ERAP1 (13) . Therefore, we measured class I levels on splenocytes and fi broblasts after treatment with IFN-γ. The results indicated similar but less pronounced diff erences in class I expression than those observed during steady-state conditions (Fig. 2, E and F) . In fact, treatment of ERAP1 −/− fi broblasts with IFN-γ for 5 d resulted in a profound increase in class I surface expression, reaching levels that were only slightly lower than those observed on similarly treated fi broblasts from ERAP1 +/+ mice (Fig. 2 F) .
We also evaluated class I expression by Con A-activated spleen lymphoblasts, which showed less profound diff erences in class I surface expression between ERAP1 −/− and ERAP1 +/+ cells than those observed during steady-state conditions (Fig. 2, A and D) . Interestingly, however, the extent of surface display of another ubiquitously expressed class Ib molecule, Qa-1 b , which binds with a highly restricted set of nonameric peptides (31) , was enhanced on lymphoblasts derived from ERAP1 mutant mice ‫%03ف(‬ increase as compared with wild-type cells; Fig. 2, A and D) .
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During these experiments we noted that heterozygous mutant animals expressed class I surface levels that were intermediate between wild-type littermates and homozygous mutant littermates (Fig. 2) . These results suggested that ERAP1 expression levels in the ER are rate limiting for the generation of class I-binding peptides, at least in the absence of infection or IFN-γ production.
Class I maturation and stability Next, we determined whether ERAP1 defi ciency was associated with alterations in class I maturation and/or stability. The rate of transport of class I molecules from the ER to the cell surface can be estimated by the sensitivity of these molecules to attack by endoglycosidase H (Endo H), which cleaves sugar moieties from class I heavy chains before, but not after, glycan modifi cations in the medial Golgi apparatus. Pulsechase experiments with spleen lymphoblasts from ERAP1 −/− and ERAP1 +/+ mice revealed comparable acquisition of Endo H resistance by K b and D b heavy chains, whereas class I heavy chains from control TAP1 −/− cells, expressing class I molecules that are largely retained within the ER (32), were profoundly defective in the acquisition of Endo H resistance (Fig. 3, A 
and B).[ I D ] F I G 3 [ / I D ]
We evaluated the stability of class I heterodimers by incubating cell extracts prepared from metabolically labeled spleen lymphoblasts at diff erent temperatures, followed by immunoprecipitation with conformation-dependent anti-K b and -D b antibodies. The results showed no detectable diff erences in this parameter between cells from ERAP1 −/− , ERAP1 +/− , and ERAP1 +/+ mice (Fig. 3, C and D) .
As an additional measurement of class I stability, we treated splenocytes with brefeldin A to prevent transport of newly assembled class I complexes to the cell surface and determined the decay of H-2K b and H-2D b molecules with conformation-dependent antibodies. The results showed a signifi cant increase in the decay of both surface K b and D b molecules from ERAP1 −/− cells as compared with ERAP1 +/+ cells (Fig. 3 E) . Nevertheless, the accelerated decay of class I molecules on ERAP1 −/− cells was substantially less pronounced than on Tapasin −/− cells (Fig. 3 E) , which express class I molecules that are predominantly loaded with low-affi nity peptides (33) (34) (35) . 
Defective presentation of self-antigens
To determine the eff ects of ERAP1 defi ciency on the presentation of self-antigens to class I-restricted CTLs, we evaluated the capacity of a panel of minor histocompatibility (H) antigen-specifi c CTL clones to react with splenocytes from wildtype and mutant animals. Because several of these CTLs recognize minor H antigens expressed in mice from the 129 but not C57BL/6 strain (36) (37) (38) , in these experiments, we used mutant and wild-type animals on a homogeneous 129 strain-derived background (see Materials and methods). Results (Fig. 4 A) . These fi ndings indicated that ERAP1 expression can have a positive, neutral, or negative eff ect on antigen presentation.
We also investigated the capacity of a panel of Qa-1 b -restricted, alloreactive CTL clones to lyse spleen lymphoblasts from mutant animals. The results revealed modest but significantly reduced capacity of each of these clones to lyse mutant cells as compared with wild-type cells (Fig. 4 B) . Subtle but reproducible diff erences in the extent of lysis of mutant cells, compared with wild-type cells, by distinct clones were observed, which is likely due to diff erences in the precise peptide selectivity of individual clones. Results shown represent data for three ERAP1 −/− mice, three ERAP1 +/+ mice, and one Tapasin −/− mouse. *, P < 0.05; **, P < 0.01.
Defective presentation of foreign antigens
To investigate the impact of ERAP1 defi ciency on the presentation of foreign antigens, we studied the capacity of mutant cells to display the immunodominant OVA-derived CTL epitope (OVA 257-264 ), after osmotic shock-mediated introduction of the native protein into the cytoplasm of cells, by H-2K b molecules at the cell surface. H-2K b /OVA 257-264 complexes were detected with an antibody that specifi cally reacts with this particular class I-peptide complex. Results demonstrated a profound defect of ERAP1 mutant cells in displaying K b /OVA 257-264 complexes at the surface (Fig. 5 A) .
[ I D ] F I G 5 [ / I D ]
Staining levels of OVA-loaded ERAP1 −/− cells were only slightly higher than OVA-loaded TAP1 −/− cells, indicating a strict requirement of ERAP1 for generating this epitope, which is consistent with prior reports (19) (20) (21) . Similarly, bone marrow-derived DCs and LPS-induced lymphoblasts from ERAP1 −/− mice were defective in presenting OVA, introduced into these cells by osmotic shock, to an OVA 257-264 -specifi c, H-2K b -restricted T cell hybridoma (Fig. 5 B) . Strikingly, cells from heterozygous mutant animals also exhibited profound defects in processing OVA for surface display by K b (Fig. 5, A and B) . Macrophages from mutant animals, infected with an OVA-expressing strain of Listeria monocytogenes, were also defective in presenting OVA antigens to OVA 257-264 -specifi c T cells, but cells from heterozygous mutants behaved more similarly to cells from wild-type animals in this assay (Fig. 5 C) .
We also tested the capacity of splenic DCs from mutant animals to cross-present OVA antigens, adsorbed to latex beads, to OVA 257-264 -specifi c T cells. The results revealed a profound defect of ERAP1 −/− DCs in cross-presenting OVA antigens (Fig. 5 D) . 
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Finally, we infected DCs from wild-type and mutant animals with the lymphocytic choriomeningitis virus (LCMV) to compare the capacity of these cells to present the immunodominant glycoprotein-derived gp33 epitope to H-2D brestricted T cells. The results showed enhanced reactivity of the gp33-specifi c T cells with ERAP1 −/− than ERAP1 +/+ cells (Fig. 5 E) . These fi ndings suggest that ERAP1 normally plays a role in destroying the LCMV gp33 epitope.
CD8 + T cell development
The surface levels of MHC class I molecules and the diversity of peptides displayed by these molecules in the thymus can have a profound impact on both positive and negative selection of CD8 + T cells (39) . Therefore, we examined CD8 + T cell development in ERAP1 mutant mice. Despite their reduced levels in MHC class I cell surface expression, the prevalence and numbers of CD8 + T cells in ERAP1 −/− mice were comparable to ERAP1 +/+ mice ( To determine whether ERAP1 defi ciency infl uences the positive selection of individual TCRs, we examined CD8 + T cell development in ERAP1 −/− mice expressing a transgenic TCR (P14) specifi c for the gp33 peptide epitope derived from the LCMV glycoprotein. These studies were performed with transgenic animals on a RAG2-defi cient background to enhance our capacity to detect defects in the positive selection of transgenic T cells. However, the results failed to reveal diff erences in the prevalence, numbers, or TCR expression levels among P14 TCR transgenic cells in ERAP1 −/− versus ERAP1 +/+ mice (Fig. 6 B and not depicted) . 
CD8 + T cell responses
Finally, we determined the impact of ERAP1 defi ciency on the generation of CTL responses in vivo. We loaded splenocytes from TAP1 −/− mice ex vivo with OVA by osmotic shock and used these cells to immunize ERAP1 −/− or ERAP1 +/+ mice. 7 d later, mice were tested for the generation of OVA 257-264 -specifi c CD8 T cell responses by stimulating splenocytes with OVA 257-264 and measuring the prevalence of IFN-γ-producing CD8 + T cells. The results showed a profound defect (three-to fourfold reduction) in the generation of OVA 257-264 -specifi c CD8 + T cell responses in vivo (Fig. 7, A 
and B).[ I D ] F I G 7 [ / I D ]
We also determined the immune response of ERAP1 −/− mice to infection by an infl uenza virus. Mice were infected intranasally with the PR8 strain of infl uenza virus and, 10 d later, lymph nodes from these animals were stimulated ex vivo with synthetic versions of a panel of H-2K b -and H-2D b -restricted peptide epitopes, and the prevalence of epitope-specifi c CD8 T cells in the cultures was evaluated by intracellular detection of IFN-γ. Our results revealed moderately reduced responses in the generation of CTL responses directed against several of the immunodominant epitopes; nonetheless, the diff erences did not reach statistical significance in any single experiment (Fig. 7, C and D) .
DISCUSSION
Our fi ndings have revealed an important in vivo role of ERAP1 in optimizing peptides for presentation by MHC class I molecules. Both H-2K b and H-2D b bind with peptides that contain hydrophobic COOH-terminal amino acid residues, which represent preferred substrates for TAP (1, 2) and ERAP1 (24). In addition, both H-2K b and H-2D b can bind with peptides that contain a proline residue in position 3, which are poorly translocated by the TAP peptide transporter (40) and, therefore, would likely be translocated as longer precursors. Consistent with these prior studies, we found that ERAP1 defi ciency resulted in a signifi cant reduction in the surface expression of H-2K b and H-2D b . In addition to its effects on class Ia molecules, ERAP1 expression also infl uenced surface expression of the class Ib molecules Qa-2 and Qa-1 b . Consistent with prior studies (19, 21) , we found that ERAP1 expression can have a positive, neutral, or negative impact on the presentation of individual class I antigens. For several of the epitopes tested, including H60 (an 8-mer peptide presented by K b ), HY (a 9-mer peptide presented by D b ), and OVA 257-264 (an 8-mer peptide presented by K b ), ERAP1 expression appeared to play an important role, as presentation of these epitopes by ERAP1 −/− cells, compared with ERAP1 +/+ cells, was reduced 80-90%. These fi ndings indicate that cytosolic proteases are unable to compensate for ERAP1 defi ciency in generating physiological levels of some epitopes. Because most minor H antigens and the epitopes recognized by alloreactive, Qa-1 b -restricted CTLs are constitutively expressed, cytosolic proteases should have sufficient opportunity to sample peptide precursors derived from these antigens that are recycled between the ER and the cytosol (41, 42) . Thus, we conclude that ERAP1 plays a ratelimiting role in the generation of a sizeable subset of peptides for presentation by MHC class I molecules to CTLs. Consistent with this conclusion, we found that ERAP1 +/− mice exhibited a phenotype that, at least in some assays, was intermediate between wild-type and mutant animals. Nevertheless, for some epitopes, ERAP1 expression had no eff ect on antigen presentation (e.g., H4 b ) or instead suppressed antigen presentation (e.g., H13 b and LCMV gp33).
Prior studies have provided confl icting results regarding the role of ERAP1 in controlling MHC class I cell surface expression (19, 21, 22) . ERAP1 knockdown by small interfering RNA in murine L cells resulted in decreased expression of both H-2K k and H-2L d (19) . Another group of 
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investigators showed that ERAP1 knockdown in K b -transfected HeLa cells did not alter K b surface expression but resulted in an increase in HLA class I surface expression (21) . Conversely, ERAP1 overexpression in H-2K b -transfected COS cells did not aff ect K b surface expression but led to signifi cant suppression of monkey class I expression (21) . In sharp contrast with the latter studies, a third group of investigators reported that ERAP1 knockdown in HeLa cells resulted in a moderate decrease in HLA class I expression (22) . We found that ERAP1 defi ciency consistently led to a reduction in the steady-state levels of K b , D b , and Qa-2 surface expression. These fi ndings are consistent with prior studies evaluating the eff ects of ERAP1 knockdown on class I expression in murine cells (19) but only partially agree with studies that have investigated the eff ects of ERAP1 knockdown or overexpression on H-2K b expression in HeLa cells and COS cells, respectively (21) .
Prior studies regarding the eff ects of IFN-γ on class I surface expression have also provided confl icting results. One group of investigators reported that ERAP1 gene silencing in H-2K b -transfected HeLa cells treated with IFN-γ resulted in signifi cant suppression of both surface K b and HLA expression (21) . However, another group of investigators reported that ERAP1 silencing in IFN-γ-treated HeLa cells resulted only in a slight diminution in HLA class I expression, which was less evident than the decrease in class I expression caused by ERAP1 silencing in untreated cells (22) . Consistent with the latter studies, we found that diff erences in class I surface expression were less evident in splenocytes and fi broblasts treated with IFN-γ and in Con A-activated T lymphocytes. Moreover, we found a slight but reproducible defect in the surface stability of K b and D b molecules on nonstimulated splenocytes from ERAP1 mutant mice but were unable to detect defects in class I maturation or stability in ERAP1 −/− Con A blasts. Collectively, our fi ndings suggest that ERAP1 plays a more important role in generating class I-binding peptides during steady-state than during conditions where IFN-γ is produced. These fi ndings were surprising because ERAP1 expression itself is profoundly induced by IFN-γ (21). One possibility is that induction of ERAP1 expression during IFN-γ treatment results in increased epitope destruction compared with the levels of epitope destruction in the absence of IFN-γ. Nevertheless, our antigen presentation and immunization studies revealed a critical role of ERAP1 for presenting individual peptides to CD8 + T cells in both the absence and presence of IFN-γ production. Thus, ERAP1 signifi cantly impacts the presentation of individual peptides but has only relatively modest eff ects on the overall capacity of the generated peptide pool to stabilize class I molecules, particularly when IFN-γ is produced. This conclusion is consistent with the idea that ERAP1 can both enhance and limit antigen presentation of individual peptide epitopes (21) .
Although diff erences between our studies and those of Serwold et al. (19) and Saveanu et al. (22) Our studies with Qa-2 and Qa-1 b molecules provide the fi rst direct evidence for a role of ERAP1 in generating peptides for surface display by class Ib molecules. Qa-2 antigens are encoded by several class Ib genes and are either linked to the cell membrane via glycosylphosphatidylinositol anchors or secreted from cells (43) . Qa-2 binds with a large array of nonameric peptides with a unique motif containing histidine at position 7 (29, 30, 44) . Expression of both secreted and glycosylphosphatidylinositol-bound Qa-2 molecules is dependent on a functional TAP peptide transporter (45), and we show here a role of ERAP1 for steady-state levels of Qa-2 surface expression, suggesting that most peptides loaded onto Qa-2 molecules are generated via the conventional class Ia antigen-processing pathway. In sharp contrast with Qa-2, Qa-1 b binds with a highly restricted set of nonameric peptides (31) . Qa-1 b predominantly binds with a single peptide, Qa-1 determinant modifi er (Qdm), derived from the leader sequence of other class I molecules (31, 46) . Despite its localization within a signal sequence, presentation of Qdm on Qa-1 b is dependent on both TAP (47) and Tapasin (48) . The production of Qdm requires several antigen-processing events. After biosynthesis and entry of the nascent class I heavy chain into the ER, the signal sequence is cleaved by signal peptidase. The resulting 24-amino acid Qdm peptide precursor, which is embedded in the membrane, is then cleaved by signal peptide peptidase, which allows the release of the NH 2 -terminal peptide fragment into the cytosol. This fragment, (Qdm is underlined) , is then processed by cytosolic proteases to generate the fi nal COOH terminus (current evidence suggests that the proteasome is not involved), resulting in a Qdm precursor containing a two-amino acid NH 2 -terminal extension (46) . Here, we demonstrate that ERAP1 expression enhances the presentation of Qdm to Qdm-dependent, Qa-1 b -restricted CTLs, suggesting that ERAP1 contributes to the removal of the two NH 2 -terminal amino acids of this peptide precursor. This conclusion is consistent with a prior study demonstrating that a Qdm precursor with a two-amino acid NH 2 -terminal extension can be processed to generate the Qdm epitope in the ER of TAP-defi cient cells (49) . However, we found that the reactivity of CTL clones with ERAP1-defi cient cells was only partially diminished, suggesting that cytosolic aminopeptidases can trim this Qdm peptide precursor as well, in a manner that is partially redundant with ERAP1. Nevertheless, it remains possible that during certain infections or in cancer cells, ERAP1 expression may represent a rate-limiting step in presenting Qdm peptides to Qa-1 b -restricted CTLs or natural killer cells expressing CD94/NKG2 receptors.
Although our studies with Qdm indicate a critical role of ERAP1 for the processing of signal sequence-derived peptide epitopes, they do not preclude the possibility that some signal sequences can be processed independently of ERAP1. Indeed, presentation of LCMV gp33, which is contained within the signal sequence of the viral glycoprotein (50) , to gp33-specifi c, D b -restricted T cells, was enhanced in ERAP1-defi cient cells, despite the requirement of TAP (51) and the proteasome (52) in the processing of this epitope. These fi ndings suggest that ERAP1 normally plays a role in destroying the LCMV gp33 epitope. In future studies, it will be interesting to infect mutant mice with LCMV and determine the strength of the CD8 + T cell response directed against the gp33 and other LCMV epitopes.
A particularly surprising result of our studies was that, at least in some assays, ERAP1 +/− mice exhibited a phenotype that was intermediate between ERAP1 +/+ and ERAP1 −/− mice. To our knowledge, this has not been described for any other mutations that aff ect the class I antigen presentation pathway. However, an intermediate phenotype, at least with respect to some aspects of antigen presentation, has been described for mice with a heterozygous mutation in the class II peptide exchange factor H-2DM (53) . Thus, ERAP1 may play a rate-limiting role in the generation of a sizable subset of peptide epitopes. Although currently unclear, the diff erential eff ects of ERAP1 heterozygozity on the processing of individual epitopes likely depends on the dose of the antigen, the method of antigen introduction, the length of antigen incubation with APC, and/or the sensitivity of the read-out assay.
In conclusion, our fi ndings have revealed an important in vivo role of ERAP1 in controlling antigen presentation by both class Ia and class Ib molecules. We demonstrated that ERAP1 expression can have a positive, neutral, or negative contribution in the generation of individual class I epitopes. Additional studies with these animals will be helpful in elucidating the role of ER-associated peptidase activity in the development of antiviral immune responses and in regulating the immunodominance hierarchy of CD8 + T cell responses in vivo.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from The Jackson Laboratory and 129S6/SvEvTac mice were obtained from Taconic. TAP1-defi cient mice (32) and Tapasin-defi cient mice (33) have been described. P14 Tg RAG2 −/− mice were obtained from Taconic and were bred with ERAP1 mutant mice to obtain P14 Tg ERAP1 −/− RAG2 −/− and P14 Tg ERAP1 +/+ RAG2 −/− mice. OT-1 Tg mice and RAG1 −/− mice were obtained from The Jackson Laboratory and bred to obtain OT-1 Tg RAG1 −/− mice. Mice were maintained in accordance with the Institutional Animal Care and Use Committee at Vanderbilt University.
Generation of ERAP1 mutant mice.
To establish an ERAP1 targeting construct, a 5.4-kb XhoI-ClaI fragment from the 5′ end of the ERAP1 gene (from exon 2 to intron 4) and a 5.3-kb NotI-SacII fragment from ARTICLE the 3′ end of ERAP1 (from the 3′ end of exon 6 to exon 11) were amplifi ed from 129S6/SvEvTac genomic DNA with Pfu Ultra DNA polymerase (Stratagene) by PCR (primers for amplifi cation of the 5′ fragment: forward primer 5′-A A C A
C T C G A G A T A C T T G C A G C A A C A C A G T T T G A A C C-C A C A G C T G -3′ and reverse primer 5′-G T G A A T C G A T G C T T A C T A G A-T G C A G A A G A C T T T T C T T T A T C G T -3′; primers for amplifi cation of the 3′ fragment: forward primer 5′-A T G A G C G G C C G C T G C C A A A T T T A T-G G A G T T T G T G T C T G T C A C T G T G -3′ and reverse primer 5′-T T A A C-C G C G G T T C A G C A A A A A T C T C T G G A C T G A G T C T G A T T -3′
). These DNA fragments, a neomycin resistance cassette (Neo), and a thymidine kinase cassette (TK) were assembled in a pBluescript II vector (Stratagene) to generate the targeting vector. The Neo cassette replaces a fragment from intron 4 up to the 5′ end of exon 6, which contains the sequence encoding the Zinc-binding motif in the putative active site of ERAP1. Strain 129S6/ SvEvTac-derived embryonic stem (ES) cells (TL-1; obtained from B. Hogan, Duke University Medical Center, Durham, NC) were transfected with the KpnI-linearized targeting vector. G418-resistant colonies were selected and isolated as described previously (32) . Genomic DNA from individual clones was digested with EcoRV and hybridized with 5′-and 3′-fl anking probes ( Fig. 1 A) , which were generated by PCR amplifi cation (primers for amplifi cation of the 5′ probe: forward primer 5′-
T A A G G T T A C A A C T G-C A T G T C T T C A T A C -3′ and reverse primer 5′-A A A C T G T G T T G C T G C-A A G T A T T C T A C -3′; primers for amplifi cation of the 3′ probe: forward primer 5′-A G T T T C T A C A A A A C A C A A A T G A T C T C C -3′ and reverse primer 5′-C T G T T T T C A G A A A T A A A C C A C A A C T T T -3′
). Chimeric mice were generated as described previously (32) , mated with C57BL/6 or 129S6/SvEvTac mice, and scored for germline transmission. Mice were genotyped by digestion of genomic DNA with EcoRV, followed by hybridization with one or both probes described above.
Analysis of ERAP1 expression by RT-PCR and immunoblotting.
For RT-PCR analysis, total RNA treated with RQ1 RNase-free DNase (Promega) was subjected to reverse transcription (Advantage RT-for-PCR kit; CLONTECH Laboratories, Inc.) and cDNA was amplifi ed by PCR with Taq polymerase (Promega). ERAP1 mRNA was amplifi ed using forward (5′-C A C T G T G A A G A T G A G T A C C T A C -3′) and reverse (5′-G T G T-G G A T A C A G G G T G A G A G -3′) primers, fl anking the deleted ERAP1 gene fragment, which produces a 551-bp fragment in wild-type animals. β-actin mRNA was amplifi ed as a control using published primers (54) .
For Western blot analysis, the rough ER from the liver was isolated as described previously (55) and the lumenal fraction was separated on 6% SDS-PAGE gels. Immunoblotting was performed with a rabbit antiserum raised against a peptide (Q N S D I E S L K A S N G D ) from the NH 2 terminus of mouse ERAP1 (Cocalico Biologicals, Inc.) or with an anti-gp96 polyclonal antibody (Santa Cruz Biotechnology, Inc.), and then probed with horseradish peroxidase-conjugated goat anti-rabbit IgG polyclonal antibody (sc-2054; Santa Cruz Biotechnology, Inc.). Blots were developed using the ECL Plus kit (GE Healthcare).
Isolation of fi broblast cell lines. Ear fi broblast cells derived from ERAP1 −/− and ERAP1 +/+ animals were immortalized by serial passage in vitro. . Cell suspensions from various tissues were prepared according to standard procedures. In some experiments cells were treated with OVA protein, synthetic peptides, recombinant mouse IFN-γ (BD Biosciences), Con A (Calbiochem), or brefeldin A (Sigma-Aldrich) before staining. Cells were stained by incubation with antibody at 4°C for 1 h followed by three washes in cold PBS supplemented with 1% fetal calf serum and 0.05% NaN 3 . For unconjugated primary antibodies, the samples were then incubated with a fl uorescently labeled secondary antibody and washed three times. After the fi nal wash, cells were analyzed using a FACSCalibur Flow System (Becton Dickinson) and data were analyzed using FlowJo software (TreeStar). Dead cells were excluded from the analysis based on their forward and sideway light scattering properties.
MHC class I maturation and thermostability assays. MHC class I maturation was examined with a modifi ed pulse-chase and immunoprecipitation procedure (32) . Con A-induced T cell lymphoblasts were starved for 1 h in methionine/cysteine-free RPMI 1640 medium (Mediatech) at 10 7 cells/ml, and then pulsed with 500 μCi/ml of a [ 35 S]methionine/cysteine mix (MP Biomedicals, Inc.) for 10 min at 37°C. After removal of one seventh of the cells for the 0 time point, the remaining cells were washed with complete RPMI 1640 medium supplemented with 10% fetal calf serum and 1 mM methionine and 1 mM cysteine, and further incubated in the same medium at 37°C. Cell aliquots were removed at diff erent time points, spun through cold PBS, and stored at −20°C. Cells were lysed in 50 mM Tris-Cl, pH 7.4, 5 mM MgCl 2 , 0.5% NP-40 (Fluka), and 1 mM PMSF (Sigma-Aldrich). After removal of insoluble materials, the lysates were precleared with normal mouse serum and immunoprecipitated with conformation-dependent anti-H-2K b (Y3) and anti-H-2D b (B22.249) antibodies. Immunoprecipitates were treated with Endo H (New England Biolabs, Inc.) at 37°C for 1 h before separation by SDS-PAGE. Precipitates were visualized by phosphorimaging and band intensities were quantifi ed with ImageQuant software (Applied Biosystems).
The thermostability of MHC class I complexes in cell extracts was examined as described previously (32, 35) . Con A-induced T cell lymphoblasts were labeled with [ 35 S]methionine/cysteine as described above for 1 h, and then washed with RPMI 1640 medium supplemented with 10% fetal calf serum and 1 mM methionine and 1 mM cysteine, and further incubated in the same medium for 2 h at 37°C. Cell lysates, generated as described above, were precleared with normal mouse serum, divided into six parts, and incubated at either 4, 15, 26, 37, 42, or 50°C for 1 h. MHC class I complexes were then precipitated with conformation-dependent anti-H-2K b (Y3) or anti-H-2D b (B22.249) antibodies at 4°C. Immunoprecipitates were treated with Endo H at 37°C for 1 h before separation by SDS-PAGE.
Thermostability of surface class I molecules was examined by culturing splenocytes with 10 μg/ml brefeldin A and staining samples after diff erent time points with conformation-dependent anti-H-2K b (Y3) or anti-H-2D b (B22.249) antibodies followed by fl ow cytometry. Data are plotted as the relative amount of class I expression with the 0 time point indicated as 100%.
In vitro antigen processing and presentation assays. To evaluate the presentation of minor H antigens, spleen cells from male ERAP1 +/+ or ERAP1 −/− mice on a homogeneous 129S6/SvEvTac background were used as stimulators for activation of minor H antigen-specifi c CTL clones, as described previously (38) . The following CTL clones were used: SP/H60 and B6-1/H60, specifi c for H60 presented by H-2K b ; B10/21M-9 and B10/21M-11, specifi c for H4 b presented by H-2K b ; B/NX-3, specifi c for H13 b presented by H-2D b ; CTL-10, specifi c for HY presented by H-2D b ; and 21M/RC6, specifi c for H4 a presented by H-2K b (36) (37) (38) . Spleen cells from female C57BL/6 mice were used as a control. Stimulators (1-10 × 10 5 cells/well) and responders (10 6 cells/well) were cocultured for 1 h, after which 10 μg/ml brefeldin A was added to the medium and cells were incubated for an additional 5 h. Cells were then surface stained with anti-CD8α mAb, washed, permeabilized with the Cytofi x/Cytoperm kit (BD Biosciences), stained with anti-IFN-γ, and analyzed by fl ow cytometry. Data are plotted as percentage CD8 + IFN-γ + cells and normalized to the response against ERAP1 +/+ cells. 
